Mifepristone Shown to Reduce A1C in Patients with Difficult-to-Control Type 2 Diabetes and Hypercortisolism
CHICAGO, June 23, 2025 /PRNewswire/ -- New findings from the CATALYST study show that the use of mifepristone resulted in improved blood glucose (blood sugar) control and weight reduction in patients with difficult-to-control type 2 diabetes and hypercortisolism. The results of the largest prospective trial of its kind were presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago, and simultaneously published in Diabetes Care®.
Among patients with type 2 diabetes, more than half do not achieve blood glucose targets as assessed by the hemoglobin A1C test, despite substantial lifestyle efforts and multiple medications. The CATALYST study explored whether hypercortisolism is a contributing factor in people with difficulty achieving A1C targets despite multiple medications. Hypercortisolism is a condition where the body produces too much cortisol, which can raise blood glucose.
Part 1 of the CATALYST study, presented at the 84th Scientific Sessions, revealed that hypercortisolism may be a significant contributing factor in one in four patients with difficult-to-control diabetes. Patients with hypercortisolism presenting as uncontrolled type 2 diabetes physically appear the same as those without hypercortisolism, but they do seem to require more medications and have more complications.
Part 2 of the CATALYST study was a randomized, prospective, placebo-controlled, double-blind multi-center trial designed to assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult-to-control type 2 diabetes. 136 participants with hypercortisolism received either mifepristone or placebo over a 24-week period to assess the impact on glycemic control and other metabolic parameters. Mifepristone is a medication that reduces the effects of cortisol and is FDA approved for the treatment of elevated blood glucose in patients with hypercortisolism and prediabetes or type 2 diabetes.
Mifepristone reduced A1C by 1.5% as compared to a reduction of 0.2% with placebo. The A1C reductions occurred even as many patients decreased or stopped other diabetes medications, including insulin. In addition, treatment of hypercortisolism with mifepristone was associated with nearly 10 pounds of weight loss and a reduction in waist circumference of more than two inches.
"These findings demonstrate a potentially promising treatment solution for patients with difficult-to-treat type 2 diabetes and hypercortisolism, a patient population frustrated with poor results of their diabetes care," said John Buse, MD, PhD, from the University of North Carolina School of Medicine and one of the authors of the study. "By treating the root cause—excess cortisol—we saw meaningful improvements in both blood glucose and weight which could be game changing when it comes to managing type 2 diabetes."
The authors note that results may translate to expanded screening for hypercortisolism in patients with type 2 diabetes. Future research is needed to understand whether patients with less advanced type 2 diabetes may experience similar benefits, if other cortisol-directed therapies offer similar results, and whether long-term treatment will provide benefits in preventing complications associated with inadequately controlled type 2 diabetes.
Research presentation details:Dr. Buse will present the findings at the following symposium along with Drs. Ralph DeFronzo, Vanita Aroda, and Vivian Fonseca:
Symposium: Treatment of Hypercortisolism in People with Difficult-to-Control Type 2 Diabetes—Final Results of the CATALYST Trial
Presented on Monday, June 23 at 3:15 p.m. CT
About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL on June 20-23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions.
About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn).
Media Contact: MCarmody@diabetes.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/mifepristone-shown-to-reduce-a1c-in-patients-with-difficult-to-control-type-2-diabetes-and-hypercortisolism-302486230.html
SOURCE American Diabetes Association
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 hours ago
- Associated Press
DermRays Celebrates 13 Years of Skincare Innovation with Exclusive Anniversary Sale and Groundbreaking 1450nm Laser Device for 2026
PLEASANTON, Calif., Aug. 15, 2025 /PRNewswire/ -- DermRays, a pioneer in at-home skincare technology, marks its 13th anniversary with a celebration of its best-selling devices and a sneak peek at its upcoming 1450nm laser skincare tool, slated for launch in early 2026. This milestone underscores the brands commitment to merging cutting-edge science with accessible beauty solutions. Anniversary Spotlight: Award-Winning Skincare Heroes To thank customers for their trust, DermRays is offering limited-time discounts on three transformative devices designed to rejuvenate skin at home: 1. DermRays Revive The first and only at-home laser with ultra-high energy for collagen regeneration. Ideal for reducing fine lines and boosting collagen, its a clinic-grade tool for a fraction of the cost. Revive uses cutting-edge 1064nm laser technology, the same as that employed by leading salon brands. 2. FusionGlow Multi-Functional Microcurrent Toning Device Beyond Microcurrent: 5 Skincare Technologies You Need. Comprehensive Skin Revitalization: Brighten, Hydrate, Rejuvenate. Achieve radiant, firm skin in 14 days with clinically visible results backed by SGS. 3. LED Light Therapy Silicone Mask Your daily skincare companion: blue, red, infrared, and mixed light for every need. Only 15 minutes a day for youthful and radiant skin. 'For 13 years, we've empowered users to take control of their skincare routines with safe, effective technology,' says Dr. Yang Lin, Brand Director at DermRays. 'Our anniversary sale is a tribute to our community-and just the beginning of whats next.' 4. The Future: 1450nm Laser Skincare Device DermRays is set to revolutionize at-home treatments again with its 1450nm laser device (expected Q1 2026). It stimulates natural collagen production to smooth fine lines, restore firmness, and reverse signs of aging. This tool will expand the brands professional-grade offerings, bridging the gap between spa treatments and home care. Join the Celebration From August 1-31, 2025, enjoy exclusive anniversary bundles and discounts on DermRays bestselling devices. Follow @DermRays on social media for giveaways and live demos. About DermRays Since 2011, DermRays has combined dermatological research with accessible technology, offering FDA/CE/UKCA-cleared, non-invasive devices for radiant, youthful skin at home. View original content to download multimedia: SOURCE DermRays
Business Wire
9 hours ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Medscape
13 hours ago
- Medscape
Diabetes Device Access Gaps Common, Affect Management
Gaps in access to prescribed diabetes technology are common, often arise from early device failure, and lead to disruptions in diabetes management, new research found. The top three reasons for the gaps were delays caused by insurer requirements for prior authorization, problems with suppliers in processing requests for refills, and delays in obtaining updated prescriptions from physicians, according to the survey results, presented by endocrinologist Andrew Welch, DO, at the American Diabetes Association 85th Scientific Sessions. The access problems were associated with higher A1c levels and lower socioeconomic status and were more common among patients who receive 30-day rather than 90-day prescriptions. 'Almost every single day this theme comes up with patients where they have prescribed diabetes technology supplies, but something happens to interrupt that supply and they're not able to use the system as intended,' said Welch, assistant professor of clinical medicine at the University of Cincinnati College of Medicine, Cincinnati, Ohio. Among the 1969 survey respondents, 42.7% of continuous glucose monitor (CGM) users and 27.3% of insulin pump users reported one or more gaps in their supplies per year, while 12.7% reported access gaps for insulin. Early device failure contributed to the problem, with 42% of CGM users and 47% of insulin pump users reporting early failure of those devices more than 10% of the time. David T. Ahn, MD, chief of diabetes services at Hoag Memorial Hospital Presbyterian, Newport Beach, California, told Medscape Medical News that those numbers are 'higher than I would have guessed, but I'm not surprised.' Both Welch and Ahn noted that some patients struggle with technology gaps and product failures more than others. 'There's a group of people who don't report any problems with this, and then there's a group who has so many problems that it can take over the whole clinical picture of that person's diabetes care,' Welch said. Ahn suggested a few workarounds, such as giving patients free samples or writing prescriptions for longer-lasting quantities of insulin and pump supplies, but that doesn't always work, he noted. For example, it's difficult to prescribe extra quantities of CGM sensors because they're labeled to last a specific number of days, Ahn explained. 'With sensors, it's a very challenging task. I personally have not seen it succeed.' Handling all the prior authorization requests can also be a challenge in Ahn's practice, which focuses on type 1 diabetes management and has made recent efforts to optimize workflow, he said. 'It's our area of passion. But imagine a general endocrinologist helping people with thyroid and pituitary conditions or a primary care provider managing every condition in the book. It makes perfect sense that prior authorizations are going to be a huge bottleneck for getting these supplies authorized,' he said. Physicians should be able to individualize diabetes device prescribing, Welch said. 'Insurance companies should cover the quantities of diabetes supplies based on published failure rate data, and/or based on physician-prescribed quantities, without hassle, prior authorization, or extra cost,' he said during his ADA presentation. Access Gaps, Device Failures Common The online 64-question anonymous survey was distributed in December 2023. Access gaps were defined as the inability to obtain prescribed supplies for diabetes technology for any reason, leading to the individual going without that supply for any duration of time. The survey was sent to about 46,000 email addresses of people in the T1D Exchange, of whom 2475 responded and 506 were excluded. The respondents had a mean age of 48.8 years, diabetes duration 27.9 years, and mean A1c of 6.6%. Three quarters were female, 78% were college graduates, and only one quarter had annual incomes below $50,000. Two thirds (64%) had private insurance. Nearly all (96%) used CGMs and 80% used insulin pumps. 'This is a very motivated group of people who are engaged with their diabetes,' Welch noted. While 57% of CGM users reported having no CGM supply access gaps in the past year, 18% reported one gap, 12% two, and 7% three. Of those reporting gaps, the average CGM user reported 2.6 access gaps per year. Access gaps for CGM were significantly more common among those with lower incomes; those of a minority race/ethnicity; and people on Medicaid or with no insurance vs those with private insurance, Medicare, or Department of Veterans Affairs (VA) benefits, and for females vs males. Gaps were less common with insulin pump supplies, with 72.7% reporting no gaps in the past year. However, 12.8% reported one gap, 7.2% two, and 2.5% three. Those with gaps reported an average of 2.4 gaps per year. Socioeconomic differences were similar to those seen with CGM access. While 87.3% of insulin users reported no gaps, 6.2% reported one gap, 3.3% two, and 3.3% three in the past year. The average was 2.2 gaps per year. 'Fortunately, this was a smaller number and frequency, but it's still somewhat discouraging to consider,' Welch said. The differences in gaps in all supply types were significant for all socioeconomic groups ( P < .05). For example, those on Medicaid had 2.1 annual CGM gaps per year, compared with 0.5 for those receiving VA health benefits. Asked what they did to avoid access gaps, patients reported calling the company to request replacements if a device fails early, extending use of the supply longer than recommended, and having their health care provider prescribe extra supplies. Some reported obtaining supplies from other people with diabetes who have extras. Access gaps were related to worse glycemic control. Individuals with A1c levels of 7.0% or less had approximately half as many gaps in access to all diabetes technology supplies and insulin compared to those with an A1c level > 7.0%. For CGM supplies specifically, the difference was 0.8 vs 1.5 gaps per year. Patients who receive 90-day supplies reported half as many gaps as those who reported receiving 30-day supplies. With CGM, the difference was 0.8 vs 1.6 annual gaps. The survey found that CGM sensor failure is very common, Welch said. Over half of respondents (50.8%) reported that their devices failed early or fell off 1%-10% of the time, another 21% reported early failures 11%-20% of the time, and only 7.3% reported zero failures. Failure rates of more than 10% of the time were seen among all CGM brands, ranging from 39% with the Dexcom G6 to 53% for Abbott's FreeStyle Libre 3. For insulin pump failures, those proportions ranged from 34% with Medtronic's MiniMed 780G to 53% for Insulet's Omnipod 5. The length of access gaps wasn't included in the T1D Exchange survey, but researchers gave patients at the University of Cincinnati Endocrinology Clinic pre-visit questionnaires that included the question. Here, 51% of 207 CGM users who responded reported at least one gap in the past 3 months, with an average duration of 16.5 days. The top reason reported was early CGM failure. For insulin pumps, 16.5% of 109 respondents reported at least one gap in the past month, with an average duration of 19.2 days. To inform his call for insurers to cover extra diabetes supplies, Welch presented published study data from the manufacturers of marketed CGMs. Reported early failure rates ranged from 13% to 23%. Using this data, he estimated the number of sensors that fail early per year ranges from 3.2 to 7.6, depending on the manufacturer. 'If we know that this is happening, and even the studies that led to the approval show this, why is it so hard to get extras, and why are we always on the edge of running out, and why can't we make this better? That's my call to action,' he concluded. Welch reported no relevant financial relationships. Ahn is a speaker for, advisor for, and/or recipient of research grants from Abbott, Ascensia, Insulet, Lilly, MannKind, Novo Nordisk, Xeris, Sequel, Lilly, Honey Health, Medtronic, and Tandem.
